SPOTLIGHT: Accentia releases positive Phase III data

Accentia Biopharmaceuticals has released positive interim data for the first 50 patients in its fast-tracked Phase III study of SinuNase. Release

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.